Author

Michael Rothe

Institution: American Society of Clinical Oncology

Observed institution: American Society of Clinical Oncology

OpenAlex ID: A5134980320

Sunitinib in Patients With Various Solid Tumors With FGFR1 / 2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

2026 · Gordan Srkalovic, Michael Rothe, et al. · JCO Precision Oncology

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

2026 · Dan S. Veljovich, Michael Rothe, et al. · JCO Precision Oncology

Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

2026 · Evan Pisick, Michael Rothe, et al. · JCO Precision Oncology

Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study

2026 · John K. Chan, Michael Rothe, et al. · JCO Precision Oncology

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

2026 · Erin F. Cobain, Michael Rothe, et al. · JCO Precision Oncology

Works count: 5

Citation count:

H-index:

I10-index: